stockportfolio.pro
Stocks / BIIB vs ONC
BIIB vs ONC
Biogen Inc. and BeOne Medicines AG side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Biogen Inc. (BIIB) | BeOne Medicines AG (ONC) | |
|---|---|---|
| Market cap | $29.3B | $27.0B |
| Revenue (latest FY) | $9.89B | $5.34B |
| Net income (latest FY) | $1.29B | $286.93M |
| Revenue growth (5y CAGR) | -6.0% | 76.8% |
| Net margin | 13.1% | 5.4% |
| Return on equity | 7.1% | 6.6% |
| P/E ratio | 21.4 | 58.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 1 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BIIB — free Open ONC — freeFrequently asked questions
Which is bigger, BIIB or ONC?
Biogen Inc. is larger by market capitalization — $29.3B versus $27.0B.
Which grows faster, BIIB or ONC?
Over the last five fiscal years, BeOne Medicines AG grew revenue faster — 76.8%/yr versus -6.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.